Open AccessBiological Evaluation of 3-Aminoisoquinolin-1(2H)-one Derivatives as Potential Anticancer Agents Authors Lyudmyla Potikha
Author(s) -
Л. М. Потиха,
AUTHOR_ID,
В. С. Броварец,
Victor Zhirnov,
AUTHOR_ID,
AUTHOR_ID
Publication year - 2021
Publication title -
french-ukrainian journal of chemistry
Language(s) - English
Resource type - Journals
ISSN - 2312-3222
DOI - 10.17721/fujcv9i2p52-63
Subject(s) - substituent , isoquinoline , melanoma , cancer research , in vitro , stereochemistry , chemistry , leukemia , aryl , cell culture , cancer , cell cycle , medicine , biology , biochemistry , alkyl , genetics , organic chemistry
Anticancer activity of a series of 3-(hetaryl/aryl)amino substituted isoquinolin-1(2H)-ones has been studied within the international scientific program “NCI-60 Human Tumor Cell Lines Screen”. Screening was performed in vitro on 60 cell lines of lungs, kidneys, CNS, ovaries, prostate, and breast cancer, epithelial cancer, leukemia, and melanoma. The most effective compounds were those with thiazolyl or pyrazolyl substituent at 3-amino group and had no substituents at C(4) of the isoquinoline cycle. We identified a new lead compound, 3-(1,3-thiazol-2-ylamino)isoquinolin-1(2H)-one 12, which effectively prevents tumor cell growth (average lg GI50 = -5.18, lg TGI = -4.1, lg LC50 > -4.0) with good selectivity.